Field Trip Psychedelics Inc. Introduces Trip, a Mobile App Designed to Expand Your Mind

Trip provides people with best-in-class tools and practices for those undertaking consciousness expanding activities such as meditation, breathwork and more.

NEW YORKSept. 2, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company”), the company redefining mental health and well-being through its ground-breaking work in psychedelics and psychedelic-enhanced psychotherapy, today announced the launch of its first-ever app, Trip. A first-of-its-kind app and experience, Trip allows people from anywhere in the world to access tools that support self-exploration and consciousness expansion through meditation, breathwork and more.

Trip blends modern understandings of neuroscience and psychology with the wisdom of experienced practitioners in meditation, breathwork and self-exploration. It supports users with intention setting, mood tracking, guided journaling and integration and personalized music that has been scientifically designed to help guide you through emotions associated with different intentions. Available now on iPhone and Android, Trip assists self-guided consciousness explorers to expand their minds, break from everyday thinking and develop a deeper connection to their emotions and psyche.

“As we began building out our network for Field Trip Health centers across North America, we saw that there is a large population of people who were keen to start, or were already actively, working with consciousness expansion and emotional processing through meditation, breathwork and legal natural or medically prescribed products. But they were often doing so by themselves and without proper support or understanding of best practices,” said Ronan Levy, Field Trip’s Executive Chairman. “So we decided to take the custom developed protocols that we were building for our Field Trip Health centers and make them available to a much broader audience. While Trip is not intended to be a substitute for properly supervised medical and psychological care, it leverages our best-in-class tools, and makes them available to anyone who may be working with consciousness-expanding practices.”

The user-friendly app allows users to start a ‘trip’ at the touch of a button and breaks the experience  into four stages: Preparation, Exploration, Reflection, and Integration. Each individual stage plays a crucial role in a user’s journey and is designed to help the users start the working of emotional processing and integration of what they experience in their consciousness expansion efforts.

The ‘Preparation’ stage helps users get centered and set an intention. The second stage, ‘Exploration,’ provides users with music that has been custom developed with LUCID, Inc. (a technology company that is developing AI-driven music experiences to support people’s mental health) and gives users the ability to record their experiences through voice memos and automatically save those with timestamps so they are easy to revisit at any time after the trip. The third stage, ‘Reflection,’ guides users through a set of structured questions to share and reflect on key insights or emotions that may have emerged during a trip, encouraging the emotional processing to begin. Finally, the ‘Integration’ enables users to revisit their experiences, and develop insights by aggregating data from recent trips.

The launch of the Trip app follows the recent opening of the company’s first stateside clinics in New York City and Los Angeles, after it opened its first location in Toronto, Ontario earlier this year.

For more information on the Trip app, visit https://www.tripapp.co/

About Field Trip Psychedelics Inc.

Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and advanced research on plant-based psychedelics through Field Trip Discovery, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com

SOURCE Field Trip Health

Related Links

https://fieldtriphealth.com

Field Trip Psychedelics Inc. Announces Closing of $11.0 million Financing, Entry into Amalgamation Agreement with Newton Energy Corporation

Both events important milestones to highly anticipated public listing

TORONTOAug. 24, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the company redefining mental health and well-being through its ground-breaking work in psychedelics and psychedelic-enhanced psychotherapy, today announced it has closed the first tranche of its Series B financing (the “Financing“), raising gross proceeds of $11.0M from a broad base of investors. The Financing was completed through a brokered private placement for which Canaccord Genuity Corp. and Stifel Nicolaus Canada Inc. jointly acted as lead agents.

The proceeds from the Financing will be used to continue Field Trip’s rollout of its Field Trip Health centers across North America, which are providing best-in-class psychedelic assisted psychotherapy, and to further advance its pioneering work with its next generation psychedelic molecule, FT-104, and its advanced research and development on psilocybin producing mushrooms in partnership with the University of West Indies.

The Company recently announced the opening of the New York location of its Field Trip Health centers, following the opening of its Toronto location earlier this year, and will shortly be announcing the opening of its Santa Monica location.

Ronan Levy, Executive Chairman of Field Trip Psychedelics, said, “Our ability to secure this private placement validates the strength of our business strategy, brand and the incredible team of physicians, psychologist, therapists, scientists and employees at Field Trip. It is also reflective of the rapidly increasing interest in the investment community in the science of psychedelics compounds and their incredible potential across a number of applications. Securing these funds strengthens our balance sheet and provides us with capital to execute against these growth plans.”

Sean Trigony, CEO and Founder of Los Angeles-based Seven Hound Ventures, which participated in the financing, said: “Field Trip’s management team has a strong track record of establishing and growing medical clinics, and the science team behind Field Trip Discovery is unparalleled. We are excited to see them applying this experience to the emerging psychedelics industry, building both the infrastructure needed to deliver treatments, as well as the next generation of psychedelic molecules targeting 5HT2A receptors.”

Amalgamation Agreement with Newton Energy Corporation

The Company also announced that it has entered into a definitive agreement dated August 21, 2020 (the “Amalgamation Agreement“) with Newton Energy Corporation (“Newton“) (TSXV: NTN.H) and Newton’s wholly-owned subsidiary, Newton Energy Subco Limited (“Newton Subco“), pursuant to which the parties intend to complete a going-public transaction for Field Trip (the “Transaction“).

The going-public Transaction is structured as a three-cornered amalgamation, which will result in Field Trip becoming a wholly-owned subsidiary of Newton by amalgamating with Newton Subco, and the security holders of Field Trip becoming security holders of Newton. In connection with the completion of the Transaction, it is intended that Newton will change its name to “Field Trip Health Ltd.” (the “Resulting Issuer”). The Amalgamation Agreement will be made available on SEDAR at www.sedar.com.

Field Trip and Newton anticipate the closing of the Transaction (the “Closing”) will occur on or about September 29, 2020. The Transaction is subject to the receipt of all necessary regulatory and shareholder approvals as well as the satisfaction of conditions to the Closing as set out in the Amalgamation Agreement.

“As pioneers in developing an entirely new industry in a profoundly transformative therapeutic modality, access to capital will be one of the key characteristics that distinguishes the leaders in the psychedelics industry,” added Levy. “Our team has demonstrated great success in raising capital to date, and our public listing will provide us with more diverse financing options that will ensure our continued success and further lower our cost of capital.”

About Field Trip Psychedelics Inc.

Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America and advanced research on plant-based psychedelics through Field Trip Discovery, we help people from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com

Forward Looking Statements

This news release contains projections and forward-looking information that involve various risks and uncertainties regarding future events and are not guarantees of future performance of the Company. These risks and uncertainties could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information. These and all subsequent written and oral forward- looking information are based on estimates and opinions of management on the dates they are made and expressed qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking information should circumstance or management’s estimates or opinions change.

SOURCE Field Trip Psychedelics Inc.

Field Trip Psychedelics Inc. Expands Stateside With Psychedelic-Enhanced Psychotherapy Clinic in New York City

Field Trip continues to usher in a new generation of effective treatments for mental health challenges with the opening of the New York location

NEW YORKAug. 13, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company”), the company redefining mental health and well-being through its ground-breaking work in psychedelics and psychedelic-enhanced psychotherapy, today announced that it is expanding stateside with the opening of a first-of-its-kind clinic in New York City. The clinic, opening under the Company’s Field Trip Health brand, exists to help people heal and overcome depression as well as other tough-to-beat mental health challenges through evidence-based, medically supervised psychedelic therapies.

Field Trip Health takes a step-by-step, integrated approach to using ketamine-enhanced psychotherapy to bring people on a path to mental wellness and healing. Evidence has shown that ketamine, a dissociative psychedelic that is also legal in the United states, is safe when administered in medically-supervised doses. Ketamine often provides rapid relief from symptoms of depression and other mental health conditions, and can create a period of neural plasticity through which people, with supportive therapies, experience improved well-being and healthier, more optimistic and more meaningful outlooks on life. Patients undergoing this therapy often see results after a single session.

“There is no better place to make our entry into the US than New York City. Known for the ‘Empire State of Mind,’ we’re excited for people here to experience the ‘Field Trip State of Mind,’ one filled with hope, optimism and wonder,” said Ronan Levy, Field Trip’s Executive Chairman. “With our Toronto clinic, we have demonstrated first-hand the transformative healing potential of psychedelics for people struggling with their mental health. Our expansion into New York gives us a unique opportunity to further demonstrate the power of psychedelic therapies, and help people in New York on their own personalized journey to healing.”

With setting playing a crucial role in the therapeutic experience of psychedelic-enhanced psychotherapy, Field Trip Health clinics are thoughtfully designed to be calm and inviting. Patient treatment is administered in a comfortable, spa-like environment that promotes tranquility and aids in the overall healing process.

“Our New York clinic includes Zen-inspired elements such as ikebana arrangements that are incorporated throughout the space to help patients ground and center themselves,” said Matt Emmer, Field Trip’s Director of Operations and Business Development, who oversaw the design and build of the New York clinic. “We created an intentional space and experience that is designed to touch people and create a resonance that we believe will promote healing. The addition of greenery and other natural elements serve to connect patients to their natural surroundings, from a custom-designed moss wall in the entryway to nature-inspired murals in each of the treatment rooms.”

The clinic also incorporates a red ochre handprint wall concept that is designed for patients to set their intentions at the start of their treatment and for closure at completion. Patients are invited to dip a hand in red ochre at each milestone moment to commemorate their journey. The wall also serves to inspire future patients embarking on the same transformative experience.

The Field Trip treatment program is an active process that spans over a 3-4 week engagement period, but can be accommodated to each patient’s schedule. Each Ketamine and Psychotherapy Exploratory session is 2-3 hours in length. Sessions are designed to get patients comfortable with the effects of the medicine and the psychedelic experience as a whole. Throughout a patient’s journey, the individual effect of the medicine will evolve and patients will go to deeper places in their therapy as they continue through the program.

“It’s a great testament to the Field Trip Health team that, despite the pandemic, we were able to complete the construction of the clinic and open its doors without significant delay in our expansion plans,” added Hannan Fleiman, President of Field Trip Health. “It is our second location that we have opened this year following the opening in Toronto. Our third location in Los Angeles is slated to open later this month, and many more will be opening across the US in the months and years to come.”

The New York clinic is located at 137 E. 25th St., 11th Floor, New York, NY 10010 and patients can book a consultation by phone (1-833-222-0084), email (nyc@fieldtriphealth.com) or online at https://www.fieldtriphealth.com/getstarted?l=new-york.

About Field Trip Psychedelics Inc.

Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and advanced research on plant-based psychedelics through Field Trip Discovery, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com

SOURCE Field Trip Health

Field Trip Psychedelics Announces New Podcast, Field Tripping: Epic Trips in Psychedelics

TORONTOJune 23, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, announced the launch of the podcast Field Tripping: Epic Trips in Psychedelics with Ronan Levy. The podcast will cover psychedelics, the people that use them, industry trends and frequently asked questions. Field Tripping is available on its website (www.fieldtripping.fm) as well as on SpotifyApple Podcasts and Google Podcasts.

The weekly podcast features conversations with celebrities, entrepreneurs, artists, scientists and medical experts about their consciousness expanding experiences on psilocybin, LSD and MDMA, while exploring how psychedelics can shift our views on sex, science, business, fitness, life and death.

The premiere episode features an interview with best selling author Don Lattin of The Harvard Psychedelic Club and Changing Our Minds — Psychedelic Sacraments and the New PsychotherapyRonan Levy speaks to Don about bad trips, the renaissance of psychedelics and the nature of addiction. Upcoming episodes include interviews with other thought leaders advancing the psychedelic movement such as:

  • Alex Ikonn: Co-founder of Intelligent Change Inc. and Co-author of The Five Minute Journal (one of Tim Ferriss’ “Tools of Titans”) and The Productivity Planner
  • Director X: Award winning Producer and Director of Superfly as well as music videos for Drake, Kanye West, Rihanna and Kendrick Lamar. Founder of Operation Prefrontal Cortex, a program harnessing the power for mindfulness and meditation to help reduce gun violence
  • Dr. Andrew Weil: Celebrity physician and author who is credited as being the “Father of Integrative Medicine”
  • Donick Cary: Emmy-winning Writer, Producer, and Director as well as the creator of the hit Netflix series “Have a Good Trip: Adventures in Psychedelics”

“We are seeing a surge of interest in psychedelics from the medical community, investors, and consumers. To help feed this appetite and give people a welcoming and open forum to talk about their experiences, we decided to launch a resource exploring how psychedelics awaken new views on sex, science, business, fitness, life, and death, on a journey with influential and inspiring guests,” said Ronan Levy, Executive Chairman of Field Trip. “We hope this continues to spark widespread interest in the therapeutic benefits of psychedelics and listeners can learn about this rapidly  growing industry.” 

About Field Trip Psychedelics Inc. 
Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and drug development and advanced research on plant-based psychedelics through Field Trip Discovery, we help people to heal and heighten engagement with the world. Learn more at https://fieldtriphealth.com

SOURCE Field Trip Psychedelics

Related Links

https://fieldtriphealth.com

Field Trip Psychedelics Inc. Announces Launch of Virtual Psychedelic Therapy and COVID-Coping Therapy

New online therapy offerings being launched in response to unique complexities of COVID-related stress, and offered for free to front-line medical workers

TORONTOApril 21, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, through its wholly-owned subsidiary, Field Trip Health Inc., today announced the launch of the world’s first virtual psychedelic therapy services.

The first two offerings that will be made available through Field Trip Health’s online platform will be the Company’s internally developed Psychedelic Breathing technique plus Integration Therapy, which has been designed to help people open up to deeper level emotions through breathing techniques, and its COVID Coping Therapy, which follows a conventional therapy format, which has been developed uniquely to help people manage the stresses of these turbulent times. Both services will be available exclusively online at www.fieldtriphealth.com/virtual-therapy, starting for people in Ontario then rolling out to the States of New York and California shortly thereafter.

Psychedelic Breathing Plus Integration Therapy

“Different breathing exercises and techniques have been known to alter consciousness and create psychedelic experiences that open people up to greater emotional awareness and depth,” said Ronan Levy, Field Trip’s Executive Chairman. “In addition, studies have shown that different breathing techniques, when combined with psychotherapy can reduce symptoms associated with Major Depressive Disorder1, PTSD2 and anxiety3, and may also improve self-esteem3. This is why we’ve worked quickly to develop techniques and protocols that we can make available online and through virtual care, particularly given that in person sessions are unavailable during these challenging times.”

As part of this therapeutic offering, Field Trip clients will follow a 30-60 minute guided Psychedelic Breathing exercise video online before participating in a 50-minute telephone/teleconference call with a therapist who will provide integration services that can be specifically tailored toward processing the emotions around COVID-19 if desired.

COVID Coping Therapy

In addition to virtual psychedelic therapy, Field Trip has announced the availability of its therapists to provide therapy specific to coping with COVID-related stress and anxiety. This therapy is designed to help people work through the many emotions that are likely coming up these days, and help them develop greater resilience until life gets back to the new post-COVID normal.

New Services Available for Free to Front-Line Medical Workers

Field Trip is also pleased to announce that it will be making initial access to these new virtual services available for free to medical workers who are on the front lines of battling the COVID-19 pandemic.

“The people who are working on the front line of our medical response to the pandemic epitomize the definition of heroism, putting their own lives on the line for the sake of others,” added Levy. “At Field Trip, we are happy to help you however we can as you save the lives of our friends and neighbours. We hope that you will take advantage of these services and tools to help you manage through these times.”

About Field Trip Psychedelics Inc.
Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and drug development and advanced research on plant-based psychedelics through Field Trip Discovery, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com and https://fieldtripdiscovery.com

1 https://www.psychiatrist.com/jcp/article/pages/2017/v78n01/v78n0107.aspx
2 https://onlinelibrary.wiley.com/doi/abs/10.1111/j.1600-0447.2009.01466.x
3 http://psycnet.apa.org/record/1996-00471-014

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtriphealth.com

Field Trip Psychedelics Inc. Announces Creation of Field Trip Discovery, the Company’s Drug Development Division

TORONTO, April 9, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, today announced the creation of Field Trip Discovery, the company’s newly formed drug development division.

Appointment of Dr. Nathan Bryson, Chief Science Officer

Field Trip Discovery will be led by Dr. Nathan Bryson, Field Trip’s recently hired Chief Science Officer. Dr. Bryson, who holds his PhD in Chemistry and Postdoctoral Associate Degree from Massachusetts Institute of Technology, has three decades of hands-on research and development experience in the biotechnology and pharmaceutical industries where he has overseen innovation, clinical development, regulatory, quality, global supply chain and medical affairs. Prior to joining Field Trip, Dr. Bryson was the Chief Science Officer for Acerus Pharmaceuticals, a Canadian pharmaceutical company with a portfolio of sexual and reproductive health prescription products. Before Acerus, Dr. Bryson previously served as Chief Science Officer at Cynapsus Therapeutics, a pharma-biotech company that was acquired by Sunovion Pharma, and at Cannasat Therapeutics, a pharmaceutical company developing novel cannabinoid therapeutics of THC and CBD.

Appointment of Dieter Weinand and Helen Boudreau to Board of Directors

The Company is also pleased to announce the appointment of Dieter Weinand and Helen Boudreau to the Board of the Directors, who along with Dr. Michael Ehlers, the Company’s Senior Strategy Advisor, will be supporting Dr. Bryson in the strategic direction of Field Trip Discovery.

Mr. Weinand is the former President, CEO and Chairman of the Board of Bayer Pharmaceuticals, AG and has 30 years of experience in senior executive roles with a number of pharmaceutical companies, including Sanofi, Otzuka and Pfizer. He has a demonstrated ability to recognize opportunity, create a vision and strategy, and mobilize organizations behind successful execution.  Mr. Weinand has launched and marketed some of the industry’s most successful products, including Lipitor, Neurontin, Abilify, and Cipro.

Ms. Boudreau joins the Company’s Board of Directors after most recently serving as Chief Operating Officer for the Bill & Melinda Gates Medical Research Institute. Prior to that role, Ms. Boudreau served as CFO for biotech companies Proteostasis Therapeutics and FORMA Therapeutics. Previously, Ms. Boudreau spent 16 years at Novartis and Pfizer, serving in strategy and senior finance roles, including Global CFO, Oncology business unit, CFO US Corporate, VP Investor Relations, VP Finance, Customer Business Unit and Commercial Operations, and VP Finance Global R&D. She has contributed to successful product launches, driven sales growth and increased profitability, integrated mergers & acquisitions, and provided leadership across Finance, IT, HR, Strategic Sourcing, Facilities, and Innovation, Quality and Process improvement.

“One of our core priorities at Field Trip is to advance the science and understanding of psychedelic compounds through evidence-based research,” said Ronan Levy, Executive Chairman of Field Trip Psychedelics. “And with the COVID-19 pandemic likely to create one of the greatest mental health challenges the world has ever seen, the need to legitimize the use of these molecules is more urgent than ever. The creation of Field Discovery led by Dr. Bryson, and supported by the many years of operational and executive experience of Dieter and Helen, in conjunction with the technical and scientific knowledge of Mike Ehlers, will help us do just that.”

“The impressive gains in the understanding of brain function, combined with the maturation and development of legitimate research in the field, is demonstrating incredible promise for  therapeutic use of psychedelic molecules like psilocybin and MDMA,” commented Dr. Bryson. “I’m excited to join the Field Trip team. Their commitment to scientific and research excellence in psychedelics, combined with its multidisciplinary structure creates numerous synergies and a dynamic environment, which will greatly advance the understanding and applications of psychedelics and their therapeutic potential. And the need for these advances is more important than ever right now.”

About Field Trip Psychedelics Inc.
Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and drug development and advanced research on plant-based psychedelics through Field Trip Discovery, we help people to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com and https://fieldtripdiscovery.com

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtripdiscovery.com

Field Trip Psychedelics Inc. Opens First of its Kind Psychedelic-Enhanced Psychotherapy Clinic in Toronto

TORONTOMarch 4, 2020 /PRNewswire/ — Field Trip Health Inc., a wholly owned subsidiary of Field Trip Psychedelics Inc., (“Field Trip” or the “Company“), the world’s first mental wellness company focused on psychedelics and psychedelic-enhanced psychotherapy, today announced the opening of its first medical centre, in Toronto, dedicated exclusively to the administration of psychedelic-enhanced psychotherapy.

The clinic was founded in response to the urgent need to combat the spiraling mental health crisis facing Canada and the world, which is a result of the limited effectiveness of current pharmacologic treatments like antidepressants. The first psychedelic that will be administered to patients, in conjunction with Field Trip’s custom developed psychotherapy protocol, is ketamine. Evidence shows that ketamine, which is a dissociative psychedelic, is safe and can provide almost immediate and enduring relief from depression symptoms. Beyond its antidepressant effects, ketamine’s  ability to promote neuroplasticity makes it a powerful tool to pair with Field Trip’s comprehensive psychotherapy program.

“Multiple evidence-based studies from world-class institutions like New York University and Johns Hopkins have demonstrated that using psychedelics and psychedelic-enhanced psychotherapy can have profound, sustained results in as little as one session in addition to having positive side effects such as improved well-being, optimism and increased neural plasticity,” said Dr. Michael Verbora, Field Trip Health’s Canadian Medical Director. “Ketamine has been identified by the former Director of the National Institute of Mental Health as one of the most important breakthroughs in antidepressant treatment in decades. As new molecules or classic psychedelics like psilocybin, LSD and MDMA get approved or legalized, we will begin to incorporate them into the practice as well.”

The Toronto centre was custom designed to offer a welcoming, world-class experience to demonstrate first-hand how psychedelics can profoundly transform the lives of patients and current approaches to mental health and wellness treatment.

“Set and setting play an instrumental role in maximizing the therapeutic experience of psychedelic-enhanced psychotherapy,” adds Ronan Levy, Executive Chairman of Field Trip. “For that reason, we have invested heavily in designing a centre that is bright and welcoming. Not only is our Toronto location an inviting space for psychedelic-enhanced psychotherapy, we believe it is one of the most beautiful medical clinics in Canada.”

Psychiatrists at the clinic have begun conducting initial consultations and the first patients to experience a ketamine experience will be seen shortly.

The clinic is located at 30 Duncan St., Suite 400, Toronto, ON, M5V 2C3, Canada and patients can book a consultation by phone (1-833-222-0084), email (hi@fieldtriphealth.com) or online at https://fieldtriphealth.com/#contact

About Field Trip Psychedelics Inc.
Field Trip is the world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and advanced research on plant-based psychedelics through Field Trip Discovery, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com and https://fieldtripdiscovery.com

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtriphealth.com

Field Trip Psychedelics Inc. Announces Closing of Oversubscribed Series A Financing

TORONTOFeb. 6, 2020 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first mental wellness company focused exclusively on psychedelics and psychedelic-enhanced psychotherapy, is pleased to announce the closing of its oversubscribed Series A financing round. The financing, which was completed through a private placement, raised $8.5M USD for the Company.

The funds will be used to execute the initial stages of Field Trip’s strategic plan to build out the world’s first network of medical centres focused exclusively on psychedelic-enhanced psychotherapy. Additionally, the financing will help fund the final construction of its research and cultivation facility at the University of the West Indies in Jamaica that is dedicated to the study of psilocybin-producing mushrooms and the discovery of novel therapeutic molecules.

“The interest we had in this financing came from a broad and varied group of academics, entrepreneurs, medical professionals, financial professionals and investment funds,” said Ronan Levy, Executive Chairman of Field Trip. “The ability to pull together such a thoughtful, supportive and diversified investor base is certainly a tribute to the team at Field Trip and the work we are doing. It also speaks profoundly to the level of interest, excitement and importance that people around the world are placing on the advancement of psychedelics and the role they may play in improving mental health, performance, general wellness and happiness.”

The financing was led by Field Trip’s founders and Singhal Health Foundation. Other notable investors in the round include Subversive CapitalSilver Spike Capital and the venture capital firm Bolt, as well as individual investors Harris Fricker, an early stage investor and pioneer in e-payments and blockchain, and Ben Greenfield, a globally recognized longevity expert and biohacker.

Triple Bottom Line: People, Planet and Profit

Additionally, Field Trip has amended its Articles of Incorporation to reflect its commitment to Triple Bottom Line operations. A “Triple Bottom Line” approach to business (commonly described as “people, planet and profit”) requires an organization to assess and account for its social and environmental impacts, in addition to its financial impacts in its decision-making processes.

Sanjay Singhal, Founder of the Singhal Health Foundation, said, “Nearly 1 in 4 people will be diagnosed with a mental health condition in their lifetime. By 2023, depressive disorders will be the single largest cause of the burden of disease globally. Addressing the global mental health crisis requires effort, work and coordination from people and organizations of all forms; academic, non-profit and for-profit. The team at Field Trip blends the right balance of a track record of success, ambition, and commitment to ethical and thoughtful business practices, which is why I’m excited to support their efforts and work closely with them to achieve their mission.”

About Field Trip Psychedelics Inc.
Field Trip is world’s first mental wellness company at the forefront of the scientific re-emergence of psychedelics and psychedelic-enhanced therapies. With Field Trip Health centres opening across North America, and advanced research on plant-based psychedelics through Field Trip Discovery, we help people, from those in treatment to those seeking accelerated personal growth, with a simple, evidence-based way to heal and heighten engagement with the world.

Learn more at https://fieldtriphealth.com and https://fieldtripdiscovery.com

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtriphealth.com

Field Trip Psychedelics Inc. Adds Michael Ehlers, Accomplished Neuroscientist and Veteran Pharmaceutical Industry R&D Executive, as Strategic Advisor

TORONTONov. 5, 2019 /PRNewswire/ — Field Trip Psychedelics Inc. (“Field Trip” or the “Company“), the world’s first integrated company in legal psychedelics and psychedelic-assisted psychotherapy, is pleased to announce the appointment of of Dr. Michael Ehlers as a Strategic Advisor to the Company.

“There are few people as uniquely qualified as Dr. Ehlers to help guide the scientific direction for Field Trip, and advance the therapeutic potential of psychedelic medicine,” said Ronan Levy, co-founder of Field Trip. “In addition to his recognized expertise in neuroscience, Mike also brings to Field Trip his accomplished career in senior scientific and business roles with some of the largest and most successful biopharmaceutical companies, along with his experience in academia. As an advisor, he will help us establish our scientific strategy, provide guidance to our growing research and development team, and leverage our research in Jamaica to create value and advance our understanding of the therapeutic and business opportunities in psychedelics.”

Dr. Ehlers has over two decades of academic and business experience in neuroscience and drug development, serving in various senior roles within the biotechnology and pharmaceutical industries. He currently serves as Chief Scientific Officer and Venture Partner at Apple Tree Partners. Prior to Apple Tree, Dr. Ehlers was Executive Vice President and Head of Research & Development at Biogen, a multinational biotechnology company specializing in the discovery, development, and delivery of therapies for the treatment of neurological diseases to patients worldwide.  Before Biogen, Dr. Ehlers served as Group Senior Vice President, Biotherapeutics and Chief Scientific Officer of Neuroscience at Pfizer where he led global research and development in neuroscience, pain and rare disease.

“Nearly 1 in 4 Americans will be diagnosed with a severe mental illness in their lifetime. Depressive disorders are one of the single largest contributors to global disease burden,” said Dr. Ehlers. “Many large pharma companies have stepped away from neuropsychiatric disease.   As a consequence, the pipeline for new drugs is limited. Therapeutic psychedelics are some of the most exciting new approaches being investigated to fight the burgeoning global mental health crisis happening right now.  It is critical that we make smart investments, develop the research rigorously, and advance this industry in a thoughtful way. I am excited to be helping Field Trip do just that.”

Before entering the private sector, Dr. Ehlers spent 12 years as Howard Hughes Medical Institute Investigator and George Barth Geller Professor of Neurobiology at Duke University.  He holds M.D. and Ph.D. degrees from the Johns Hopkins University School of Medicine, one of the leading research institutions investigating the potential therapeutic benefits of psychedelics.

About Field Trip Psychedelics, Inc.
Field Trip is the world’s first integrated company in legal psychedelics. With current and planned operations in North America, the Caribbean and Europe, Field Trip’s goal is to become the recognized global leader in the medical and therapeutic applications of psychedelics.
Learn more at https://fieldtriphealth.com

SOURCE Field Trip Psychedelics Inc.

Related Links

https://fieldtriphealth.com